UNSPSC 51442002: Fludeoxyglucose (18f) or fludeoxyglucose f-18

This classification denotes a fluorine-based medical imaging agent and tracer, commonly used in Positron Emission Tomography (PET), a preparation which US FDA regulates under Unique Ingredient Identifier 0Z5B2CJX4D. European Medicines Agency schedules Fludeoxyglucose (18f) in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07680MIG. The term FLUDEOXYGLUCOSE (18F) is an International Non-Proprietary Name (see WHO INN reference publication, Volume 4, No. 3 1990, List 30.) FLUDEOXYGLUCOSE F-18 remains the US FDA Preferred Term for this commodity.

Fludeoxyglucose (18f) bears US NLM identifiers UMLS ID C0046056 and NCI Concept Code C964. Most nations, for tariff and trade purposes, schedule Fludeoxyglucose (18f) under HS 28444000 and SITC 52519. SMILES: C([C@H]([C@H]([C@@H]([C@H](C=O)[18F])O)O)O)O.

UNSPSC 51442002 Fludeoxyglucose (18f) or fludeoxyglucose f-18 is a Commodity code that represents a positron-emission-tomography (PET) radiopharmaceutical used in medical imaging; however, the most recent state and local solicitations tagged under this code bear no substantive relationship to the code's nominal scope. The two recent opportunities on record—one from Broward County Aviation Department for Rapiscan X-ray inspection-system maintenance services and one from Pasco County for copper sulfate chemicals—address equipment maintenance and industrial water-treatment chemicals respectively, neither of which aligns with radiopharmaceutical procurement or PET imaging supply chains. This mismatch suggests either consistent misclassification in the tagging systems of the issuing bodies or a data-entry error in the opportunity records themselves.

State and local procurement under UNSPSC 51442002 shows negligible recent activity tied to the code's actual scope. No opportunities for fludeoxyglucose F-18 supply, hospital radiopharmaceutical services, or PET imaging agents appear in the recent solicitation record. Vendors pursuing radiopharmaceutical or PET-imaging-related state and local contracts should verify coding in each RFP or RFQ directly rather than rely on this code's recent history to surface relevant opportunities.